Pharma/biotech companies are increasingly looking to access large-scale data sets to fill gaps in their computational biology capabilities. Be prepared for the investment.
- How CGT Developers Should Think About Manufacturing Models, Hybrid Strategies, And Scale
- Enhancing Gene And Cell Therapies With Circular RNA-Based Gene Expression
- FDA Explains How To Respond To Form 483 Observations In New Draft Guidance
- Organizing Digital Systems Around Novel Modalities
- Achieving Annex 1 Compliance In Sterile Manufacturing, Part 1: Common Compliance Failures
- Hormuz Deal Brings Cautious Relief To Pharma Packaging Supply Chains
- PUPSIT In Cell & Gene Therapy: Risk Reduction Or Operational Complexity?
- Is Your AI Model Trustworthy And Credible In GMP Processes?
CELL & GENE ARTICLES, APP NOTES, CASE STUDIES, & WHITE PAPERS
-
![GettyImages-637368252 Scientist Monitoring Equipment Readings, CQV Concept]( "Biocompatibility Studies On CHO Cell Culture In X-ray Irradiated BioBLU® Single-Use Bioreactors")
Biocompatibility Studies On CHO Cell Culture In X-ray Irradiated BioBLU® Single-Use BioreactorsIn cell culture, the leakage of toxic or inhibitory chemicals from single-use bioreactors has become a growing concern. Explore recommendations for leachable studies.
-
![GettyImages-1590576166 cells, research, lab, assay]( "Rapid Production Of Assay Ready Cells For GPCR Drug Discovery")
Rapid Production Of Assay Ready Cells For GPCR Drug DiscoveryAccelerate drug discovery by leveraging transiently transfected assay-ready cells. This method improves assay sensitivity and reduces variability for GPCRs.
-
![GettyImages-1213680755-scientist-gloves-assay-cell-culture]( "Speeding Up Safety: An Evaluation Of Mycoplasma Technology")
Speeding Up Safety: An Evaluation Of Mycoplasma TechnologyRapid mycoplasma testing enhances cell and gene therapy safety by reducing turnaround time, minimizing sample needs, and delivering sensitive, reliable contamination detection across diverse matrices.
-
![GettyImages-2189138619 lab]( "The Effect Of Mixing Homogeneity In Retentate Vessel")
The Effect Of Mixing Homogeneity In Retentate VesselDiscover a novel analytical method enhancing TFF diafiltration insights that deliver superior mixing, reliable scale-up, and breakthrough interpretation of diavolume performance.
-
![DNA strands, genetic biotechnology, gene cell-GettyImages-2154784301]( "Correlating NGS Success With Sample Input Quality: A Large Scale Study")
Correlating NGS Success With Sample Input Quality: A Large Scale StudyDIN values offer a data‑backed way to identify which DNA samples are ready for successful sequencing. With strong correlations to sequencing performance, DIN thresholds help streamline workflows.
-
![Thermo Fisher - SUB]( "Scalability From 5L To 50L Using The DynaDrive Single-Use Bioreactor")
Scalability From 5L To 50L Using The DynaDrive Single-Use BioreactorMaintaining a consistent bioprocess when scaling from 5 L to 50 L is achievable. This study shows how to successfully scale processes while maintaining cell density, viability, and protein production.
-
![GettyImages-1220382102-lab-research]( "A Scalable Platform To Revolutionize Gene Therapy Manufacturing")
A Scalable Platform To Revolutionize Gene Therapy ManufacturingDiscover how our innovative rAAV production platform can revolutionize your gene therapy pipeline with unparalleled yield, quality, and scalability.
-
![GettyImages-2174865889-scientists-laboratory-equipment-analysis]( "Make Your Production Sites Adaptable And More Efficient")
Make Your Production Sites Adaptable And More EfficientPharma faces mounting complexity and tighter margins, demanding agile, future-ready production. Discover how smart manufacturing enables faster adaptation and continuous therapy availability.
-
![GettyImages-515631085-cryopreservation-cryo-cold]( "ATMP Cryopreservation Done Right - Best Practice In Small Volume Cryo-Freezing")
ATMP Cryopreservation Done Right - Best Practice In Small Volume Cryo-FreezingExplore best practices for cryopreserving small-volume advanced therapy medicinal products (ATMPs), emphasizing sterility, cell viability, and efficiency using innovative single-use systems and aseptic connectors.
-
![GettyImages-1626470215-cluster-cells-stem-cells-blue]( "Molecular Approaches To Streamline Cell Therapy Product Analytical Testing")
Molecular Approaches To Streamline Cell Therapy Product Analytical TestingLearn how rapid molecular methods of cell therapy testing like qPCR for mycoplasma, sterility, and lentiviral quantification are key to accelerating product release and timely treatment delivery.
NEWSLETTER ARCHIVE
- 07.03.26 -- Hormuz Deal Brings Cautious Relief To Pharma Packaging Supply Chains
- 07.02.26 -- New Podcast Episodes: A Midyear Look At Life Sciences, Derisking CNS Drug Development, In Vivo Gene Editing
- 07.02.26 -- Why Improving Drug Delivery Remains A Major Opportunity In Oncology
- 07.01.26 -- In Vivo Gene Editing Is Moving From Promise To Proof
- 06.30.26 -- Cell Therapy Without The Cells: Building A Therapeutic Secretome
- How CGT Developers Should Think About Manufacturing Models, Hybrid Strategies, And Scale
- In Vivo Gene Editing Is Moving From Promise To Proof
- Driving Gene Therapy Beyond Rare Disease Will Define The Next Era Of CGT
- CGT Manufacturing Shifts From Capacity To Strategy
- Dr. Peter Marks On Why Gene Therapy May Need A New Regulatory Playbook
CELL AND GENE CONTENT COLLECTIONS
While there are opportunities to scale, there are also manufacturing gaps, capacity issues, and production timelines that require improvement to do so. And then, of course, there’s cost. Because scale up and scale out are significant to everyone in the sector, we’ve curated insightful editorial that addresses the most important aspects of scalability.
More Content Collections
